

The table below contains a listing of recent congress presentations, not yet published in manuscript form, related to our work in osteoporosis. Presentations referenced may contain investigational and post-hoc analyses reporting information regarding approved and non-approved uses of our products and are not intended to promote any product or indication.

Conference, Year	Presentation/ Abstract Number	Presentation Format	Authors	Title
ORS 2021	0472	Poster	Arlt H, Lv Z-T, Hu D, Ominsky MS, Winzenrieth R, Weiss R, Baron R, Lanske B, Besschetnova T	Comparative Effects of Abaloparatide and Teriparatide on Cortical and Trabecular Bone
AMCP Nexus 2020	M12	Poster	Ramachandran S, Williams SA, Weiss R, Wang Y, Zhang Y, Nsiah I	Gender Disparities in Osteoporosis Screening & Management Among Older Adults
NAMS 2020	P-39	Poster	Williams SA, Weiss R, Wang Y, Cui L, Nichols H, Gernert A	Real-World Outcomes of Patients New to Osteoporosis Therapies
WCO 2020	OC4	Oral presentation	Winzenrieth R, Ominsky MS, Wang Y, Humbert L, Weiss R	Differential Effects of Abaloparatide and Teriparatide on Cortical Volumetric BMD and Bone Strength Indices in the Proximal Femur by DXA-Based 3D Modeling
ASBMR 2020	P-707	Poster	Ozgurel SU, Sato A, McAndrews K, Halladay D, Cregor M, Solis AV, Gortazar A, Bellido T	Abaloparatide is more effective than PTH in restoring bone formation and bone structural properties, but both agents similarly correct the impaired bone material properties and citrate content in mice with Type 1 Diabetes
ASBMR 2020	P-643	Poster	Winzenrieth R, Ominsky MS, Yang Y, Humber L, Weiss R	Heterogeneity in the Cortical Response to Abaloparatide and Teriparatide in the Proximal Femur by DXA-Based 3D Modeling
Society of Toxicology 2020	3403/P216	Poster	Li G, Gelow K, Atkari K, Dandekar D, Troy S	Safety Assessment of Abaloparatide-Solid Microstructured Transdermal System for the Treatment of Osteoporosis in Hra:(NZW) SPF Rabbits
ACR 2019	2220	Poster	Lane NE, Weiss R, Mitlak B, Wang Y, Valenzuela GJ, Deal C	Abaloparatide Followed by Alendronate on Bone Mineral Density and Fracture Incidence in Postmenopausal Women with Osteoporosis and Osteoarthritis

ASBMR 2019	LBSUN-1081	Poster	Wein MN, Severe N, Karabacak NM, Castro CA, Janton C, Balani D, Lanske B, Scadden DT, Kronenberg HM	Mass Cytometry Reveals Rare Bone Marrow Stromal Subpopulations Targeted by Abaloparatide and Teriparatide
ASBMR 2019	SUN-880	Poster	Lv Z, Hu D, Zhang J, Brooks D, Bouxsein M, Lanske B, Gori F, Baron R	In Vivo Comparison of Skeletal and Osteocytic Responses to Abaloparatide and PTH 1-34
ENDO 2019	4574	Oral Presentation	Lane NE, Mitlak B, Weiss RJ, Wang Y, Valenzuela GJ, Bilezikian JP	The Effect of Abaloparatide on Bone Mineral Density and Fracture Incidence in Postmenopausal Women with Osteoporosis and Osteoarthritis